Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).

Trial Details

NCT ID
NCT05829629
Phase
PHASE1
Sponsor
BlueSky Immunotherapies GmbH
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • FluBHPVE6E7
  • Placebo
Locations (sample)
  • Bratislava, Slovakia|48.14816,17.10674

Key Eligibility Criteria

  • Females, 18-49 years of age with HPV16 infection and cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atyp…
  • HPV16 infection has been confirmed at least twice by a validated HPV test separated by at least 3 months
  • Satisfactory colposcopy
  • No clinically significant out of range haematological, renal or hepatic laboratory tests

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →